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Abstract 
Background: Tissue kallikrein-related peptidases 4, 5, 6 and 7 (KLK4-7) strongly 
increase the malignancy of ovarian cancer cells. Deciphering their downstream 
effectors, we aimed at finding new potential prognostic biomarkers and treatment 
targets for ovarian cancer patients. KLK4-7-transfected (OV-KLK4-7) and vector-
control OV-MZ-6 (OV-VC) ovarian cancer cells were established to select differentially 
regulated factors. 
Methods: With three independent approaches, PCR arrays, genome-wide microarray 
and proteome analyses, we identified 10 candidates (MSN, KRT19, COL5A2, 
COL1A2, BMP5, F10, KRT7, JUNB, BMP4, MMP1). To determine differential protein 
expression, we performed Western blot analyses, immunofluorescence and 
immunohistochemistry for 4 candidates (MSN, KRT19, KRT7, JUNB) in cells, tumor 
xenografts and patient-derived tissues. 
Results: We demonstrated that KLK4-7 clearly regulate expression of MSN, KRT19, 
KRT7 and JUNB at the mRNA and protein levels in ovarian cancer cells and tissues. 
Protein expression of the top-upregulated effectors, MSN and KRT19, was 
investigated by immunohistochemistry in patients afflicted with serous ovarian cancer 
and related to KLK4-7 immunoexpression. Significant positive associations were 
found for KRT19/KLK4, KRT19/KLK5 and MSN/KLK7. 
Conclusion: These findings imply that KLK4-7 exert key modulatory effects on other 
cancer-related genes and proteins in ovarian cancer. These downstream effectors of 
KLK4-7, MSN and KRT19, may represent important therapeutic targets in serous 
ovarian cancer. 
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Background 
Ovarian cancer is the fifth leading cause of cancer-associated deaths in women in the 
United States, with 14,070 estimated deaths in 2018, and the most lethal 
gynecological malignancy (1). The majority (>70%) of ovarian cancer patients are 
diagnosed at an advanced stage of the disease (FIGO III/IV). After standard treatment 
for advanced ovarian cancer, including cytoreductive surgery and platinum-containing 
chemotherapy, the cure rate is only 14% and thus has marginally changed in the last 
25 years (2). Therefore, it is imperative to find new therapeutic targets to ameliorate 
these patients’ prognosis. 
 
The tissue kallikrein-related peptidases (KLKs) are a family of 15 closely related serine 
proteases, KLK1-15 (3), and show great promise as cancer biomarkers and 
therapeutic targets for ovarian cancer due to their biological substrates and signaling 
interactors present in the ovarian tumor microenvironment (4). At least 12 KLKs 
(KLK2-8, 10, 11, 13-15) are upregulated in ovarian cancer (3, 5). In particular, elevated 
KLK4-7, 10 and 15 expression correlates with unfavorable prognosis and late-stage 
disease (6, 7). KLK4 and KLK7 expression mediates resistance to the first-line 
chemotherapeutic paclitaxel in ovarian cancer (8, 9). Accumulating evidence suggests 
that KLK4-7 together are part of an enzymatic cascade that promotes ovarian cancer 
(10). In fact, simultaneous overexpression of KLK4-7 in OV-MZ-6 ovarian cancer cells 
significantly increases cell invasion in vitro (11) and tumor burden and metastatic 
spread in tumor xenograft models compared to KLK4-7-deficient control tumors (11, 
12). Moreover, KLK4-7-overexpressing ovarian cancer cells exhibit decreased cell 
adhesion and integrin expression as well as resistance to paclitaxel (13). Secreted 
proteome (secretome) and proteolytic profile (degradome) analyses revealed that 
KLK4-7 overexpression induced transforming growth factor beta-1 (TGFβ-1) signaling 
in ovarian cancer cells, suggesting a pronounced, yet non-degrading impact on the 
secretome and an association between KLK expression and the TGFβ-1 network in 
the tumor microenvironment (14). 
 
Thus, tumor-associated KLK4-7 overexpression significantly enhances ovarian cancer 
cell functions and the progression of this disease. However, the underlying 
mechanisms are not yet fully elucidated. KLK-mediated pericellular proteolysis occurs 
in various aspects of cancer cell proliferation, invasion and metastasis and in a 
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complex microenvironment (15, 16). The objective of this study was to determine 
genes and pathways regulated by KLK4-7 and to investigate the expression of these 
regulated factors in tumor tissues of ovarian cancer patients, potentially finding new 
biomarkers and therapeutic targets to treat the advanced stages of ovarian cancer. 
 
Material and methods 
Cell culture. Human OV-MZ-6 ovarian cancer cells were established from ascites of 
a patient with serous adenocarcinoma of the ovary and cultured as reported (17). OV-
MZ-6 cells were stably co-transfected with an expression vector, pRcRSV (Invitrogen, 
Dreieich, Germany) harboring human full-length cDNAs of KLK4-7, resulting in OV-
KLK4-7 cells (11). Cells transfected with the vector only were used as controls (OV-
VC cells) (11). 
 
RT² Profiler PCR array. RNA was extracted from the OV-MZ-6-derived cell lines using 
the RNeasy Mini kit (Qiagen, Hilden, Germany) and the QIAcube fully automated spin 
column system (Qiagen), followed by DNase (Qiagen) treatment according to the 
manufacturer’s instructions. Reverse transcription was performed using a RT² First 
Strand kit (Qiagen) and subsequent quantitative PCR analysis using a RT² SYBR 
Green PCR Mastermix (Qiagen) and primer pre-coated RT² Profiler PCR array plates 
(Qiagen), with 84 pathway- or disease-focused genes per plate. Three different 
human-specific PCR arrays were conducted: TGFβ/bone morphogenic protein (BMP), 
protease-activated receptor (PAR) and epithelial-to-mesenchymal transition (EMT) 
signaling pathways. 
 
Quantitative RT-PCR. RNA was isolated from three biological replicates as described 
and reverse transcription was performed with the Cloned AMV First-Strand cDNA 
synthesis kit (Invitrogen). Quantitative RT-PCR analysis was performed using 
Universal ProbeLibray Probes (Roche, Mannheim, Germany), Brilliant III Ultra-Fast 
SYBR Green Low ROX Mastermix (Agilent Technologies, Waldbronn, Germany), 25 
ng/well cDNA and 20 µM primers (Table S1). 
 
Microarray. RNA was isolated as described above and a custom Agilent 4x180k oligo-
array was performed using three biological replicates as reported (18). Microarray data 
were processed with Agilent’s Feature Extraction software (v10.7), and differential 
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expression determined using a Bayesian adjusted t-statistic within the ‘Linear Models 
for Microarray Data’ (LIMMA) R-package. Normalized gene expression data of the 
experiment are Minimum Information About a Microarray Experiment (MIAME) 
compliant. Probes with a fold change (FC) of ≥2/≤-2 and FDR (false discovery rate) 
corrected P≤0.05 between both groups were identified as significantly different. 
Pathway and gene enrichment analysis were used for functional gene annotations. 
Data have been deposited at the Gene Expression Omnibus (GEO) repository with 
the accession number GSE109261. 
 
Secretome and degradome profiling. The secretome and degradome analysis has 
been performed previously (14). The fold-changes were calculated for each replicate 
or averaged and included in Table 1. 
 
Western blot analysis. Cell lysates of the OV-MZ-6-derived cell lines were generated 
using Tris-buffered saline containing 1% Triton X-100 and 0.1% complete proteases 
inhibitor cocktail (Roche). Protein concentrations were determined with the 
bicinchoninic acid protein assay (Thermo Fisher, Dreieich, Germany) and 40 µg/lane 
of protein was electrophoresed on a 12% SDS polyacrylamide gel and transferred onto 
polyvinylidene difluoride (PVDF) membranes (Millipore, Darmstadt, Germany) via 
semi-dry blotting. PVDF membranes were incubated with primary antibodies (Table 
S2) overnight at 4°C and the secondary antibody (HRP-conjugated anti-mouse/rabbit 
IgG, 1:5,000, Millipore) 1 h at room temperature. Proteins were visualized using 
enhanced chemiluminescence substrate (Thermo Fisher) with a V3 Western Workflow 
(Bio-Rad, Dreieich, Germany). For Coomassie Blue staining, SDS polyacrylamide gels 
were fixed in 50% methanol plus 10% acetic acid, stained with 0.1% Coomassie R-
250 blue (Thermo Fisher) solution (40% ethanol plus 10% acetic acid) and destained 
in 40% methanol plus 10% acetic acid. 
 
Immunofluorescence. Immunofluorescence staining was performed as reported (13) 
using primary (Table S2) and secondary antibodies (Alexa488-conjugated anti-
mouse/rabbit IgG, 1:1,000, Life Technologies, Melbourne, Australia), followed by DAPI 
counterstaining. 
 
6 
Immunohistochemistry using tumor xenograft tissues. Immunohistochemistry on 
tumor xenograft tisues was performed as reported (14) using primary (Table S2) and 
HRP-conjugated anti-mouse/rabbit IgG (Dako, Hamburg, Germany). Antibody binding 
was visualized by 3,3′-diaminobenzidine (Dako), followed by Mayer’s hematoxylin 
counterstaining. 
 
Immunohistochemistry using patient-derived tissues. Formalin-fixed, paraffin-
embedded ovarian cancer tissues were obtained from the archives of the Department 
of Pathology of the Technical University of Munich. Tissue microarrays were produced 
as described previously (19). Briefly, samples were deparaffinized, blocked by 3% 
hydrogen peroxide and pressure-cooked in 10 mM citrate buffer, pH 6.0, for antigen 
retrieval. Samples were incubated with primary antibodies (Table S2) for 1 h and HRP-
conjugated anti-mouse/rabbit IgG (Zytomed, Berlin, Germany) for 30 min at room 
temperature in a wet chamber. Antibody binding was visualized by 3,3′-
diaminobenzidine (Dako), followed by Mayer’s hematoxylin counterstaining. 
 
Statistical analysis. Data were analyzed for statistical significance using SPSS 22.0. 
For comparison of mean values, the independent-samples T-Test was used. 
Differences with a p-value ≤0.05 were considered statistically significant (P≤0.05 is 
marked as *, P≤0.01 as ** and P≤0.001 as ***). 
 
Results 
KLK4-7 overexpression induces significant changes in gene expression in 
ovarian cancer cells 
To identify genes and/or pathways regulated via simultaneous overexpression of 
KLK4-7 in ovarian cancer cells, three different PCR array analyses, targeting the 
TGFβ, PAR and EMT pathways, were performed. KLK4-7 gene expression was 
confirmed on the mRNA (Table S3) and protein levels via qPCR (13) and ELISA (11) 
respectively. In total, 74 genes were found to be more than 2-fold deregulated in OV-
KLK4-7 compared to OV-VC cells (Table S4, Figure S1). In parallel, an independent 
genome-wide RNA microarray (Figure S2) and a secretome (14) analysis were 
performed, and 10 candidates were identified to be differentially expressed across all 
three approaches (Table 1). Pathway and gene enrichment analyses identified 
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different molecular and cell functions, canonical pathways and upstream regulators 
being significantly regulated upon KLK4-7 expression (Table S5). To validate 
differential regulation of the candidate genes, qPCR analysis was performed using 
different probes and RNA samples compared to the PCR arrays. MSN, KRT19, 
COL5A2, COL1A2, BMP5 and F10 were significantly upregulated in OV-KLK4-7 
compared to OV-VC cells in both PCR arrays and qPCR (Figures 1A-F). KRT7, JUNB, 
BMP4 and MMP1 were significantly downregulated in OV-KLK4-7 compared to OV-
VC cells in both PCR arrays and qPCR (Figure 1G-K). Thus, at the mRNA level, all 
10 candidate genes were found to be significantly differentially expressed following 
overexpression of KLK4-7 in ovarian cancer cells. 
 
KLK4-7 overexpression induces upregulation of MSN and KRT19 as well as 
downregulation of KLRT7 and JUNB proteins in ovarian cancer cells 
Next, we sought to investigate the protein expression pattern of the highest 
deregulated candidate genes in all three independent analytical approaches. Thus, 
MSN, KRT19, KRT7 and JUNB were selected for analyses by Western blotting 
(Figure 2) and immunofluorescence (Figure 3A) using the same human-specific 
monoclonal antibodies (Table S2). A strong upregulation of MSN and KRT19, together 
with downregulation of KRT7 and JUNB, was observed in OV-KLK4-7 compared to 
OV-VC cells. Downregulation of JUNB expression was more pronounced at the protein 
than mRNA level in OV-KLK4-7 cells, probably due to post-transcriptional regulation 
events. Immunofluorescence microscopy revealed specific staining patterns of the 
analyzed proteins (Figure 3A). While MSN showed a distinct cell membrane-
associated staining, JUNB staining was associated with cell nuclei. Accordingly, MSN 
is a membrane-organizing extension spike protein, whereas JUNB is a transcription 
factor. KRT19 and KRT7 are members of the large keratin gene family encoding 
typical intermediate filament proteins of epithelia. Thus, as expected, both KRT19 and 
KRT7 showed a cytoplasmic staining pattern, with a perinuclear staining for KRT7. 
In a previous study, OV-KLK4-7 and OV-VC cells were injected into NOD/SCID mice 
to form tumors in vivo (12). Formalin-fixed, paraffin-embedded tumor xenograft tissues 
from that study were used for immunohistochemical analysis of the 4 candidate 
proteins in this study using the same antibodies as above (Table S2). A strong staining 
of MSN and KRT19, together with a weak staining of KRT7 and JUNB was observed 
in OV-KLK4-7-derived tumor tissues compared to OV-VC-derived tumor tissues 
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(Figure 3B). Overall, expression of MSN, KRT19, KRT7 and JUNB proteins was 
demonstrated to be clearly different in OV-KLK4-7 cells compared to OV-VC cells, as 
assayed via Western blotting, immunofluorescence and immunohistochemistry. 
 
Protein expression patterns of KLK4-7, MSN and KRT19 in tumor tissue of 
patients afflicted with advanced ovarian cancer 
We sought to compare the relationship of KLK4-7 expression with that of MSN and 
KRT19 respectively, rather than the downregulated KRT7 and JUNB, on the protein 
level of all factors by immunohistochemistry in formalin-fixed, paraffin-embedded, 
patient-derived tissues. In previous studies, we have evaluated protein expression of 
KLK5 (19), KLK6 (20) and KLK7 (21) in ovarian cancer by immunohistochemistry. In 
the present study, we used a previously established protocol for KLK4, which has 
recently been used to assess KLK4 expression in breast cancer tissues (22). In 
addition, we established immunohistochemical protocols for MSN and KRT19 
respectively. In Figure 4, examples of MSN (A-C) and KRT19 (D-F) staining patterns 
are presented (for KLK4 see Figure S3), with an occasional distinct polar association 
of MSN with the cell membrane and KRT19 and KLK4 in the cytoplasm. For estimation 
of MSN, KRT19 or KLK4 immunoreactivity, a semi-quantitative score, based on 
staining intensity and percentage of positively stained cancer cells was used (for 
details see Methods). Scoring of KLK5, KLK6 and KLK7 immunostaining was 
previously done in a similar manner. In total, data for all factors were obtained from 
tumor tissues of 66 patients afflicted with advanced serous ovarian cancer (FIGO 
III/IV). The relationship of either KLK4, KLK5, KLK6 or KLK7 immuno-reactive score 
values with those of MSN and KRT19 is summarized in Table 2. A significant 
association was found for KLK7/MSN (P=0.001), KLK4/KRT19 (P=0.010) and 
KLK5/KRT19 (P=0.030), while KLK6/MSN (P=0.056) and KLK6/KRT19 (P=0.075) 
showed a trend towards significance. In all cases, a lower KLK expression was 
associated with a lower expression of MSN or KRT19 and vice versa. In case of 
KLK4/MSN, in the KLK4 high-expressing group, a distinctly elevated number of MSN 
high-expressing cases (23 high versus 16 low) was observed. Similarly, KRT19 high-
expressing cases were distinctly more frequent in the KLK7 high-expressing group (21 
high versus 15 low). We also performed an in silico correlation analysis using the 
TCGA and ICGC high grade serous ovarian cancer transcriptome data sets (23, 24). 
Here, both MSN and KRT19 were found to be positively associated with KLK5, KLK6, 
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and KLK7 (data not shown). Taken together, the immunohistochemistry data and the 
later in silico analyses are in line with the results obtained with the OV-MZ-6 ovarian 
cancer cell line and strongly indicate that overexpression of KLK4-7 in ovarian cancer 
patients is associated with an elevated MSN and KRT19 protein expression. 
 
Discussion 
Most members of the KLK serine protease family, including KLK4, 5, 6 and 7, are 
upregulated in ovarian cancer. Crosstalk between KLK4-7, possibly together with other 
proteases, may lead to modulation of diverse signaling pathways accompanied by 
complex interactions promoting both stimulatory and inhibitory signals. There may be 
a link between KLKs and the steroid hormone receptor pathway (25). These may 
contribute to tumorigenesis by affecting several tumor-associated processes, such as 
proliferation, survival, migration and invasion. In fact, our present results demonstrate 
that overexpression of KLK4-7 significantly regulates expression of other tumor-
associated factors and pathways in OV-MZ-6 cells. 
 
Using two different methods for mapping mRNA expression, qPCR arrays and a 
genome-wide RNA microarray, we identified several genes whose transcript might be 
affected by KLK4-7 overexpression. In addition to these RNA-based methods, we also 
considered data from our previous proteome study (14), in which the secretome profile 
of cell-conditioned medium of OV-KLK4-7 versus control OV-VC cells has been 
analyzed by mass spectrometry. We selected 10 candidates for further analysis. Six 
of the 10 selected genes (MSN, KRT19, COL5A2, COL1A2, BMP5, F10) were 
upregulated upon KLK4-7 overexpression, while the other 4 genes were 
downregulated (KRT7, JUNB, BMP4, MMP1). MMP1 was only found significantly 
downregulated in the PCR array but not in the microarray and secretome analyses, 
thus was not further considered. Four of these genes (MSN, KRT19, KRT7, JUNB) 
are not annotated as secreted proteins. Therefore, one might have expected that these 
proteins would not be detectable in the secretome analysis. However, MSN and 
KRT19 were present in significantly higher amounts and KRT7 in significantly lower 
amounts in cell-conditioned medium on comparison of OV-KLK4-7 versus control OV-
VC cells. This is in line with the detected differential mRNA expression. The presence 
of these proteins in cell-conditioned medium may result from exosomes and/or 
increased cell death during culture of the cells in serum-free medium to obtain the cell-
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conditioned medium. It should be noted that soluble protein fragments of several 
keratins, including KRT19, can be detected in the circulation of cancer patients and 
are, in fact, used to monitor tumor load and disease progression in certain tumor types 
(26). 
Differential mRNA expression of all 10 candidate genes was verified by qPCR, 
whereby different primers, different probes and also independently prepared mRNA 
for cDNA synthesis were used. We selected the two top-upregulated (MSN, KRT19) 
and two top-downregulated (KRT7, JUNB) genes to analyze whether this differential 
mRNA pattern in both cell lines is also reflected at the protein level in in vitro cell culture 
and tumor xenograft models. Indeed, we validated a strong increase of MSN and 
KRT19 and a clear decrease of KRT7 and JUNB in OV-KLK4-7 versus control OV-VC 
cells by Western blot analysis, immunofluorescence and immunohistochemistry. 
 
Jun proteins (c-Jun, JunB and JunD) are important in the regulation of cell proliferation, 
apoptosis and angiogenesis and associated with tumorigenesis and progression of 
several tumor types. Together with Fos proteins, they form different homo- and 
heterodimers, named AP-1 transcription factors (27). In combination with c-Fos, c-Jun 
expression supports tumorigenesis, whereas JunB is an inhibitor of cell division, an 
inducer of senescence and a tumor suppressor (28-31). In the present study, JunB 
showed downregulation upon overexpression of KLK4-7 in ovarian cancer cells, which 
may increase cell proliferation and promote tumorigenesis. 
 
Among the top-regulated candidates, we identified a pair of genes, KRT7 and KRT19, 
encoding the intermediate filament proteins keratin 7 and 19, whose expression was 
inversely affected by overexpression of KLK4-7. The family of keratins consists of two 
major subgroups, the type I and type II keratins that form obligate heterodimers by 
pairing of a type I with a type II keratin, which then assemble into filamentous polymers. 
Besides being important structural stabilizers of epithelial cells, keratins also have 
other cellular functions, including maintenance of cell integrity, positioning of 
subcellular organelles, signaling and protection from apoptosis (26). In malignant 
tumors, keratin 8/18 is the most prominent keratin pair. However, keratins 7 (type II) 
and 19 (type I) are frequently expressed and also occur as a keratin pair. Interestingly, 
in the absence of keratin 7, keratin 19 hetero-dimerizes with keratin 8 (26). Our findings 
may indicate that reduction of keratin 7 expression with concomitant increase of 
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keratin 19 may induce a switch for keratin 7/19 (and 8/18) to a novel keratin dimer 
composed of keratin 8/19 (and 8/18). Besides ductal breast carcinomas and lung 
adenocarcinomas, non-mucinous ovarian carcinomas tend to lose keratin 7 
expression upon metastasis (32). 
Keratin 19 lacks the carboxy-terminal tail domain typical for all other keratins and 
functionally overlaps with keratin 18. As stated above, cancer cells release soluble 
keratin 19 fragments. Serum levels of keratin 19 fragments (which are detected by the 
so-called Cyfra 21-1 assay) were found to be significantly higher in patients with 
ovarian cancer compared with those with benign ovarian disease (33, 34). 
Furthermore, Cyfra 21-1 serum levels were significantly higher in serous versus non-
serous types of ovarian cancer and higher in advanced (FIGO III/IV) versus early 
(FIGO I/II) stage disease. Interestingly, high pre-operative serum Cyfra 21-1 levels 
were associated with increased chemoresistance of ovarian cancer patients. Thus, 
increased release of keratin 19 fragments into the circulation may be an indicator of a 
more aggressive disease. In the study by Wu et al. (34), Cyfra 21-1 was proposed to 
be of prognostic value. However, the analyzed patient cohort was very heterogeneous 
encompassing different subtypes of ovarian cancer as well as early and advanced 
disease stages. To test whether increased serum levels of keratin 19 fragments are of 
prognostic relevance, more homogeneous patient cohorts using only advanced high-
grade serous ovarian cancer patients have to be analyzed. In hepatocellular 
carcinoma, pre-operative serum Cyfra 21-1 levels were positively correlated with 
KRT19 expression. Additionally, KRT19 was linked to poor prognosis, cancer cell 
proliferation, invasion, TGFβ signaling and EMT. KRT19-positive cells showed 
sensitivity to TGFβ receptor inhibition, which suppressed TGFβ signaling and reduced 
tumor growth in a xenograft model (35). 
Our data strongly suggest an association between KLK4-7 and KRT19 expression in 
ovarian tumor tissues. As shown by immunohistochemical analysis, expression of both 
KLK4 and KLK5 were significantly and positively associated with KRT19 expression; 
KLK6 showed a trend towards significance. In the case of KLK7, the group of KLK7 
high-expressing cases encompassed distinctly more high KRT19-expressing tumors 
(21 high versus 15 low). Taken together, the published data and our findings in the 
present study indicate that upregulation of KRT19, induced by KLK4-7 overexpression, 
may increase malignancy of ovarian cancer cells and furthermore be an explanation 
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for our previous report from Loessner et al. (13) that OV-KLK4-7 ovarian cancer cells 
were less sensitive to paclitaxel treatment compared to OV-VC cells. 
 
Besides KRT19, MSN was identified as a strongly upregulated factor upon 
overexpression of KLK4-7. MSN is a membrane-organizing extension spike protein, 
which belongs to the ERM family encompassing three homologous members: ezrin, 
radixin and moesin. MSN functions as a cross-linker between the plasma membrane 
and the cytoskeleton and is involved in cell-cell recognition, signaling and cell 
movement. High expression of MSN was positively correlated with disease 
progression in different tumor types (36, 37). In ovarian cancer, ezrin and moesin 
showed strong expression in 49% and 48% of tumor tissues respectively, and their 
expression correlated with reduced overall survival (38). Similar to KRT19, we 
observed distinct associations of MSN expression with KLK4-7 expression in tissues 
from serous ovarian cancer patients. MSN significantly and positively correlated to 
KLK7 expression; KLK6 showed a trend towards significance). In case of KLK4/MSN, 
a distinctly elevated number of MSN high-expressing cases (23 high versus 16 low) 
was observed in the KLK4 high-expressing group. This finding may indicate that upon 
overexpression of KLK4-7 an increased MSN expression promotes a malignant 
phenotype of ovarian cancer cells. 
In muscular dystrophy, MSN, TGFβ and collagen type-I levels were found to be 
elevated and linked to cell motility and invasion. Enhanced immunoexpression of MSN 
and collagen type-I was observed in patient tissues, suggesting that MSN might be a 
potential disease-associated biomarker (39). Dislocation of ERM proteins into the 
cytoplasma alters cell-to-cell communications and induces cytoskeleton remodeling, 
subsequently promoting cancer progression and metastatic processes like EMT. 
Upregulation and phosphorylation of MSN, and other ERM proteins, are prerequisites 
for a malignant phenotype in other tumor types, for example in glioblastoma (40), 
melanoma (41), cervical cancer (42), oral squamous cell carcinoma (43), diffuse large 
B-cell lymphoma (44) and breast cancer (45). MSN was positively correlated with 
tumor grade of breast tumors, depicting a cytoplasmic and membranous staining 
pattern mostly in normal adjacent tissues (45). Interaction of the tumor suppressor 
BRCA1 with ERM proteins reduced spreading and motility of breast cancer cells (46). 
ERM proteins also mediated multidrug resistance of breast cancer cells as they control 
both membrane insertion and functionality of P-glycoprotein that actively unloads 
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chemotherapeutics from resistant cancer cells (47). The study by Ansa-Addo et al. 
(48) showed that MSN is translationally regulated by TGFβ and required for induced 
regulatory T cell (iTreg) development and TGFβ signaling. Loss of MSN caused a 
significant reduction in the generation of iTregs due to inefficient TGFβ signaling. This 
reduced amount of iTregs resulted in a delayed tumor recurrence in a melanoma 
animal model (48). The findings from our study are in accordance with these above 
mentioned reports and suggest that ERM proteins control various signaling pathways, 
including TGFβ and EMT cascades. Downregulation and/or inactivation of ERM 
proteins may be effective in abolishing tumor growth. Our results demonstrate that 
MSN is significantly upregulated upon KLK4-7 overexpression in ovarian cancer cells 
compared to controls. So far, upregulation of MSN has not been shown in ovarian 
cancer cells compared to normal ovarian tissue and if the upregulated MSN is in its 
phosphorylated form. This will be subject of future studies. Increased MSN levels may 
be responsible for tumor progression and metastasis in concert with elevated 
expression of KLK4-7 in ovarian tumors and thus may be combated by combination 
therapy regimes using MSN or KLK inhibitors. Reduction of MSN, as induced via 
inhibition of KLKs, might also lead to a decreased generation of iTregs delaying tumor 
recurrence and might reverse multidrug resistance of tumor cells. 
 
The herein identified KLK4-7-related factors are key members of the TGFβ and BMP 
network that is a well-known modulator of EMT in cancer progression and metastasis. 
The TGFβ receptor activin receptor-like kinase 1 (ALK1) interacts with BMP9 and 
BMP10 and is therapeutically pursued to interfere with TGFβ and BMP binding and 
downstream signaling, thus inhibiting tumor angiogenesis. Combination of the ALK1 
inhibitor, dalantarcept, with doxorubicin and cisplatin enhanced the efficacy of these 
chemotherapeutics and impaired growth of solid tumors in different animal models 
(49). The BMP-SMAD pathway and its activation status are associated with enhanced 
cell proliferation and poor prognosis in serous ovarian cancer, thus representing a 
potential therapeutic target for this disease (50). The multi-kinase inhibitors 
dorsomorphin and LDN-193189, which also interfere with BMP signaling, have shown 
efficacy in an intraperitoneal xenograft model and in resensitizing platinum-resistant 
ovarian cancer cells, thus are promising alternatives for the adjuvant therapy of 
chemoresistant disease (51). The combination of TGFβ/BMP inhibitors with KLK-
targeting agents may be an alternative to treat ovarian cancer. However, one needs 
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to have in mind that different members of the TGFβ superfamily have overlapping and 
opposing functions in a tissue-specific context and TGFβ receptor signaling is 
controlled by a variety of extracellular factors like proteases, growth factors, cytokines 
and ECM molecules (52). Their roles in cancer cell proliferation, metastatic and 
immuno-regulatory processes are complex and tightly regulated by the tumor 
microenvironment. 
Future research will include a functional characterization of the top-regulated factors 
in other KLK-expressing cell lines or treating OV-KLK4-6 cells with recombinant TGFβ. 
As we only focused on factors significantly regulated in all three approaches, future 
studies might validate other significant genes from the PCR array that are involved in 
KLK-mediated functions, e.g. cancer cell invasion and resistance to paclitaxel. In 
addition, some of the previous studies did not distinguish expression in individual 
ovarian cancer histotypes, which is an essential factor to understand the relevance of 
expression within specific ovarian cancer histotypes. However, we evaluated the 
expression of KLK4-7 in high-grade serous ovarian cancer cells and tissues in a 
homogenous patient cohort. 
 
Conclusions 
The association of the expression of different KLKs with those of MSN and KRT19 
indicate that coordinate presence of KLK4-7 may be critical to induce the observed 
modulations of KLK-targeted genes. In fact, in contrast to KLK4-7 overexpression in 
ovarian cancer cells, overexpression of individual KLKs (e.g. KLK7) or other 
combinations (e.g. KLK5 + KLK7) does not lead to increased tumor growth and spread 
in an ovarian cancer xenograft model (P. Prezas, A. Krüger, V. Magdolen, unpublished 
results). KLK-mediated extracellular proteolysis is involved in many steps of cancer 
development and progression, including cell growth, angiogenesis, invasion and 
metastasis. In addition to degradation effects, KLKs can also activate signaling 
cascades, including TGFβ and EMT pathways, independent of their degrading 
function (14). Overexpression of KLK4-7 distinctly regulates the expression of other 
factors in OV-MZ-6 ovarian cancer cells, which are strongly associated with 
tumorigenesis. This may explain the findings in our previous publications (11-14, 53). 
In an in vitro invasion assay (11), we observed a significantly increased invasive 
behavior of OV-KLK4-7 versus control OV-VC cells. In tumor xenograft studies (11, 
12), we detected a significant role of KLK4-7 expression in tumor growth and spread. 
15 
Our data imply that KLK4-7 exert key modulating effects on cancer-related targets and 
provide preclinical evidence for combination therapy regimens of MSN or TGFβ/BMP 
inhibitors with KLK-targeting agents for women afflicted with ovarian cancer. 
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Figure legends 
Figure 1. Analysis of mRNA expression in OV-KLK4-7 versus control OV-VC 
cells via PCR array and qPCR. Selected genes identified as being deregulated in 
OV-KLK4-7 (red columns) versus OV-VC (blue columns) cells in the PCR array 
were validated by qPCR using independently isolated RNA. OV-KLK4-7 cells 
displayed significant upregulation of MSN (A), KRT19 (B), COL5A2 (C), COL1A2 
(D), BMP5 (E) and F10 (F) as well as downregulation of KRT7 (G), JUNB (H), BMP4 
(J) and MMP1 (K) compared to OV-VC cells (* P≤0.05; ** P≤0.01; *** P≤0.001). 
 
Figure 2. Western blot detection of differential protein expression of MSN, 
KRT19, KRT7 and JUNB in OV-KLK4-7 versus control OV-VC cells. Coomassie 
Blue staining (A) showed no obvious difference between OV-VC and OV-KLK4-7 
protein patterns (40 µg protein/lane). Western blot analyses demonstrated 
upregulation of MSN (B) and KRT19 (C) and downregulation of KRT7 (D) and JUNB 
(E) in OV-KLK4-7 compared to OV-VC cells. GAPDH served as reference protein 
for equal loading and uniform transfer. Degradation products of the analyzed 
proteins by limited proteolysis were co-visualized with MSN (B), KRT7 (D) and JUNB 
(E). 
 
Figure 3. Visualization of differential protein expression of MSN, KRT19, 
KRT7 and JUNB in OV-KLK4-7 versus control OV-VC cells and tumor 
xenograft tissues by immunofluorescence and immunohistochemistry. (A) 
An increased staining of MSN and KRT19 and a decreased staining of KRT7 and 
JUNB was observed in OV-KLK4-7 compared to OV-VC cells. MSN was cell 
membrane-associated, while JUNB was located in the nucleus. KRT19 and KRT7 
showed a cytoplasmic staining pattern, with a perinuclear staining for KRT7 (scale 
bars, 25 µm). (B) In accordance with the immunofluorescence results, MSN and 
KRT19 showed increased and KRT7 and JUNB decreased immunohistochemical 
staining in OV-KLK4-7-derived tumors compared to OV-VC-derived tumors (scale 
bars, 100 µm; inserts: scale bars, 25 µm). 
 
Figure 4. Immunohistochemical detection of MSN and KRT19 protein expression 
in high-grade serous ovarian cancer tissue samples. (A-C) Representative 
immunoexpression of MSN at low (A) and high (B) levels. Occasionally, a distinct polar 
23 
association of MSN with the cell membrane was observed (C). (D-F) Representative 
micrographs corresponding to low (D), moderate (E) and high (F) cytoplasmic KRT19 
immunoexpression (scale bar, 100 µm). 
